The oncology landscape is undergoing a paradigm shift as biopharmaceutical companies prioritize precision over broad spectrum treatments. In this high stakes environment, the Antibody Drug Conjugates Market Share has become a critical indicator of a company’s dominance in next generation cancer therapy. These complex molecules, which integrate the targeting accuracy of monoclonal...